Long Daniel D. sold $115K of SEPN
Long Daniel D. (SVP, Drug Discovery) sold 3,333 shares of Septerna, Inc. (SEPN) at an average of $34.36 ($34.10–$34.81, $0.11M total) across 2 trades on 2026-07-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific open-market sale size, dates, and weighted-average price range under a pre-arranged 10b5-1 plan; it is not a fundamental update.
Market read
Primarily a sentiment/positioning datapoint for SEPN; likely low incremental impact versus broader company fundamentals.
What to watch
The article doesn’t disclose whether other insiders sold/bought around the same window, nor does it provide context on total compensation or prior plan size.
Background
This is an SEC Form 4 insider transaction disclosure for Septerna, Inc. (SEPN).
Ticker impact
Septerna insider Form 4 shows SVP Drug Discovery Long Daniel D sold 3,333 shares on 2026-07-01 under a 10b5-1 plan.
Low likelihood of a sustained price move solely from this sale; any impact is likely short-lived/immaterial.
The filing is a pre-arranged 10b5-1 open-market sale; the article provides no new operational, regulatory, or financial catalyst beyond the transaction details.
Market effects
Minimal; single-company insider transaction without sector-wide information.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can coincide with near-term caution; traders may watch for follow-on sales or changes in trading patterns.
Key entities
- issuerSepterna, Inc.
Subject of the Form 4 insider transaction; SVP Drug Discovery sold shares under a 10b5-1 plan.
- insiderLong Daniel D.
SVP, Drug Discovery; executed open-market sale of 3,333 shares on 2026-07-01.